

# ADVANCES IN PARASITOLOGY



Edited by J.R. BAKER R. MULLER D. ROLLINSON

## Advances in PARASITOLOGY

VOLUME 58

#### **Editorial Board**

- M. Coluzzi, Director, Istituto de Parassitologia, Università Degli Studi di Roma 'La Sapienza', P. le A. Moro 5, 00185 Roma, Italy
- **C. Combes**, Laboratoire de Biologie Animale, Université de Perpignan, Centre de Biologie et d'Ecologie Tropicale et Méditerranéenne, Avenue de Villeneuve, 66860 Perpignan Cedex, France
- **D.D. Despommier**, Division of Tropical Medicine and Environmental Sciences, Department of Microbiology, Columbia University, 630 West 168th Street, New York, NY 10032, USA
- J.J. Shaw, Instituto de Ciências Biomédicas, Universidade de São Paulo, av. Prof. Lineu Prestes 1374, 05508-900, Cidade Universitária, São Paulo, SP, Brazil
- **K. Tanabe**, Laboratory of Biology, Osaka Institute of Technology, 5-16-1 Ohmiya Asahi-Ku, Osaka, 535, Japan
- P. Wenk, Falkenweg 69, D-72076 Tübingen, Germany

# *Advances in* PARASITOLOGY

#### Edited by

### J.R. BAKER

Royal Society of Tropical Medicine and Hygiene, London, England

### R. MULLER

London School of Hygiene and Tropical Medicine, London, England

and

## D. ROLLINSON

The Natural History Museum, London, England

#### **VOLUME 58**



Amsterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore Sydney Tokyo

ELSEVIER B.V.	ELSEVIER Inc.	ELSEVIER Ltd	ELSEVIER Ltd
Sara Burgerhartstraat 25	525 B Street	The Boulevard	84 Theobalds Road
P.O. Box 211, 1000 AE	Suite 1900, San Diego	Langford Lane, Kidlington	London WC1X 8RR
Amsterdam, The Netherlands	CA 92101-4495, USA	Oxford OX5 1GB, UK	UK

© 2004 Elsevier Ltd. All rights reserved.

This work is protected under copyright by Elsevier Ltd, and the following terms and conditions apply to its use:

#### Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier's Rights Department in Oxford, UK: phone (+44) 1865 843830, fax (+44) 1865 853333, e-mail: permissions@elsevier.com. Requests may also be completed on-line via the Elsevier homepage (http://www.elsevier.com/locate/permissions).

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

#### **Derivative Works**

Tables of contents may be reproduced for internal circulation, but permission of the Publisher is required for external resale or distribution of such material. Permission of the Publisher is required for all other derivative works, including compilations and translations.

#### Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier's Rights Department, at the fax and e-mail addresses noted above.

#### Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 2004

British Library Cataloguing in Publication Data A catalogue record is available from the British Library.

ISBN: 0-12-031758-3 ISSN: 0065-308X

⊕ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Pointed in Creat Patrice

Printed in Great Britain.

## **CONTRIBUTORS TO VOLUME 58**

- J.-C. ANTOINE, Unité d'Immunophysiologie et Parasitisme Intracellulaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France
- J. BETHONY, Cellular and Molecular Immunology Laboratory, "René Rachou" Research Centre FIOCRUZ, Barro Preto – CEP 30190-002, Belo Horizonte, Brazil
- S. BROOKER, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
- N. COURRET, Unité d'Immunophysiologie et Parasitisme Intracellulaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France
- A. J. DAVIES, School of Life Sciences, Kingston University, Penrhyn Road, Kingston upon Thames, Surrey, KT1 2EE, UK
- B. FRIED, Department of Biology, Lafayette College, Easton, Pennsylvania 18042, USA
- T. K. GRACZYK, The W. Harry Feinstone Department of Molecular Microbiology and Immunology, and Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205, USA
- P. J. HOTEZ, Department of Microbiology and Tropical Medicine, The George Washington University, Washington DC 20037, USA
- T. LANG, Unité d'Immunophysiologie et Parasitisme Intracellulaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France
- P. T. MONIS, Australian Water Quality Centre, South Australian Water Corporation and Cooperative Research Centre for Water Quality and Treatment, Private Mail Bag 3, Salisbury, SA 5108, Australia

- E. PRINA, Unité d'Immunophysiologie et Parasitisme Intracellulaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France
- N. J. SMIT, Department of Zoology, Rand Afrikaans University, P.O. Box 524, Auckland Park 2006, South Africa
- R. C. A. THOMPSON, WHO Collaborating Centre for the Molecular Epidemiology of Parasitic Infections, Veterinary and Biomedical Sciences, Murdoch University, Murdoch, WA 6150, Australia

## PREFACE

The opening paper in this volume concerns the intricate interactions between *Leishmania* and antigen-presenting cells of the mammalian host. Jean-Claude Antoine, Eric Prina, Nathalie Courret and Thierry Lang from the Institut Pasteur, Paris provide a detailed overview of how *Leishmania* spp. interact with two cell types, macrophages and dendritic cells, and describe some of the strategies used by *Leishmania* spp. to survive in these inducible or antigen-presenting cells. This is a fascinating account of the complex interactions that can occur between host and parasites. The authors highlight a number of questions and challenges in need of further research.

In the next paper, Andrew Thompson of the University of Melbourne, Australia and Paul T. Monis from the Australian Water Quality Centre, Salisbury consider the variation observed in Giardia and the implications for taxonomy and epidemiology. Giardia is an intestinal parasite often encountered in humans, which can cause acute or chronic diarrhoea, dehydration, abdominal pain, nausea, vomiting and weight loss. Awareness of the parasite goes back a long time; indeed Giardia might have been observed as far back as 1681 by Antonie van Leeuwenhoek. It is interesting to read how the story has unfolded over the years and to appreciate the considerable ongoing debate that has concerned Giardia especially relating to the taxonomy, phylogeny and host specificity. The application of new molecular tools for identification and diagnosis are helping to unravel the mysteries of the transmission and host specificity of this parasite. Undoubtedly the findings have relevance to the control of giardiasis. The authors propose that this new information be reflected in the redesignation of several species of Giardia described previously.

Bernard Fried at Lafayette College, Pennsylvania and Thaddeus Graczyk of Johns Hopkins University, both in the USA, continue the series of reviews on echinostomes (previous reviews in volumes 29, 38 and 49 of *Advances in Parasitology*). The 10 species of *Echinostoma* considered in the present review do not include the most important medical or veterinary parasites, although they can play a significant role in causing disease in waterfowl and aquatic mammals. Some species are also widely used as experimental models since the complete life cycles can be conveniently maintained in the laboratory. This has enabled them to be used to help elucidate many aspects of trematode biology including physiological, biochemical, immunological and molecular studies. These aspects, as well as systematic and descriptive studies, are comprehensively reviewed.

Human hookworm infection is extremely common with estimates of over 700 million cases in the tropics and subtropics. Often occurring together with other intestinal helminths, hookworm infection remains an important public health problem. Indeed there has been a gradual realization that the effects of infection are greater than had been assumed in the past. In this review, Simon Brooker from the London School of Hygiene and Tropical Medicine, UK, Jeffrey Bethony from the "René Rachou" Research Centre FIOCRUZ, Brazil and Peter Hotez from The George Washington University, USA provide an extensive overview of current knowledge highlighting recent advances in our understanding of the biology, immunology, epidemiology and public health significance of hookworm infections. It is extremely encouraging that large-scale treatment campaigns are under way around the world and the authors consider the advantages of regular population-based chemotherapy.

Nico Smit, of Rand Afrikaans University in South Africa, and Angela Davies, of Kingston University in the UK, complete the volume with an account of the relatively little-known but fascinating gnathiid isopods. These small crustacea have free-living, non-feeding adults and parasitic juveniles, comprising several larval stages, which feed on the blood and tissue fluids of fishes. Apart from the sometimes considerable pathogenic effects to the fish of this parasitism, at least one genus of gnathiid (*Gnathia*) serves as a vector of the apicomplexan protozoan *Haemogregarina bigemina*, a widespread parasite of teleosts. Smit and Davies suggest that further investigation of the capacity of gnathiids to act as vectors of other parasitic groups is warranted.

> John Baker Ralph Muller David Rollinson

This Page Intentionally Left Blank

## CONTENTS

Contributors to Volume 58	v
Preface	vii

## *Leishmania* spp.: on the Interactions They Establish with Antigen-Presenting Cells of their Mammalian Hosts

Jean-Claude Antoine, Eric Prina, Nathalie Courret and Thierry Lang

	Abstract	2
1.	Introductory Remarks	3
2.	The M $\Phi$ s as Host Cells for <i>Leishmania</i> spp	17
3.	The M $\Phi$ s as Cells Presenting <i>Leishmania</i> Antigens	24
4.	Ability of Infected M $\Phi$ s to Destroy Leishmania Parasites	
	They Harbour	32
5.	The DCs as Cells That Can Also Shelter Leishmania spp	37
6.	Role of DCs in the Presentation of Leishmania Antigens	
	to Naive and Activated Specific T Lymphocytes	41
7.	The Potential of Infected APCs or APCs Loaded with Leishmania	
	Antigens as Vaccines or Therapeutic Agents	50
8.	Conclusions	53
	Acknowledgements	55
	References	56

## Variation in *Giardia*: Implications for Taxonomy and Epidemiology

R.C.A. Thompson and P.T. Monis

	Abstract	70
1.	Introduction	70
2.	Current Taxonomy and Nomenclature	75

	05
	88
	105
	119
	121
•	· · · · · · · · · · · · · · · · · · ·

# Recent Advances in the Biology of *Echinostoma* species in the "revolutum" Group

Bernard Fried and Thaddeus K. Graczyk

	Abstract	140
1.	Introduction	140
2.	Echinostoma caproni	142
3.	Echinostoma trivolvis	152
4.	Echinostoma paraensei	165
5.	Echinostoma revolutum	169
6.	Echinostoma friedi	174
7.	Echinostoma miyagawai	175
8.	Echinostoma echinatum	176
9.	Echinostoma parvocirrus	177
10.	Echinostoma luisreyi	177
11.	Echinostoma jurini	178
12.	Concluding Remarks	178
	Acknowledgements	179
	References	180

#### Human Hookworm Infection in the 21st Century

Simon Brooker, Jeffrey Bethony and Peter J. Hotez

	Abstract	198
1.	Introduction	199
2.	Biology	201
3.	Immune Responses to Hookworm	211
4.	Epidemiology and Transmission Dynamics	220
5.	Public Health Consequences	233
6.	Global Distribution and Disease Burden	242
7.	Strategies for Control	250

8.	Future Directions	261
	Acknowledgements	262
	References	263

#### The Curious Life-Style of the Parasitic Stages of Gnathiid Isopods

N.J. Smit and A.J. Davies

	Abstract	289
1.	Introduction	290
2.	Gnathiid Phylogeny, Taxonomy and Morphology	303
3.	Life Cycles of Gnathiids	317
4.	Adaptation of Juveniles to Blood Feeding	334
5.	Pathology and Transmission of Infection Associated	
	with Blood Feeding	358
6.	Behaviour of Gnathiid Juveniles and the Role of	
	Cleaner Fishes in their Removal from Clients	369
7.	Conclusion	373
	Acknowledgements	377
	References	378
_		
INDE	X	393
CON	FENTS OF VOLUMES IN THIS SERIES	405

The colour plate section appears between pages 50 and 51.

This Page Intentionally Left Blank

## *Leishmania* spp.: on the Interactions They Establish with Antigen-Presenting Cells of their Mammalian Hosts

Jean-Claude Antoine\*, Eric Prina, Nathalie Courret and Thierry Lang

#### Unité d'Immunophysiologie et Parasitisme Intracellulaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France

	Abs	tract	2
1.	Intro	oductory Remarks	3
	1.1.	The Life Cycles of <i>Leishmania</i> spp	3
	1.2.	"Classical and Natural Experimental Models" of	
		Leishmaniases	6
	1.3.	Cells Containing Leishmania or Leishmania	
		Antigens in Infected Mice	8
	1.4.	Background on M $\Phi$ s and DCs: The Sentinels of the Body	10
	1.5.	Background on the Biosynthesis of MHC Class I and II	
		Molecules by APCs and Formation of Peptide–MHC	
		Molecule Complexes	14
2.	The	$M\Phi s$ as Host Cells for <i>Leishmania</i> spp	17
	2.1.	Binding and Internalization of Promastigotes	
		and Amastigotes	17
	2.2.	The Formation of PVs After Promastigote or Amastigote	
		Phagocytosis and the Adaptation of Parasites to These	
		Intracellular Niches	19
З.	The	$M\Phi s$ as Cells Presenting <i>Leishmania</i> Antigens	24
	3.1.	PVs and the Ag Presentation Machinery	24
	3.2.	MHC I Ag Presentation by Infected M $\Phi$ s	25
	3.3.	MHC II Ag Presentation by Infected M $\Phi$ s	26
	3.4.	Expression of Co-stimulatory Molecules by Infected M $\Phi s$	29
	3.5.	<i>In vivo</i> Data	31

<sup>\*</sup>Author for correspondence. E-mail: jantoine@pasteur.fr

4.	Ability of Infected M $\Phi$ s to Destroy <i>Leishmania</i> Parasites	
	They Harbour	32
	4.1. The Different Pathways Leading to the Development of	
	Leishmanicidal Properties	32
	4.2. Mechanisms of <i>Leishmania</i> Killing	35
	4.3. How <i>Leishmania</i> Evade the Killing Mechanisms?	36
	4.4. In Susceptible Mice, $M\Phi$ s Can Follow an Alternative	
	Activation Pathway Leading to Uncontrolled	
	Parasite Growth	37
5.	The DCs as Cells That Can Also Shelter Leishmania spp	37
	5.1. Binding and Phagocytosis of Promastigotes	
	and Amastigotes	37
	5.2. Phagosomal Compartments Housing Parasites in DCs	40
6.	Role of DCs in the Presentation of Leishmania Antigens	
	to Naive and Activated Specific T Lymphocytes	41
	6.1. Ability of <i>Leishmania</i> spp. to Induce DC Maturation	
	and Migration	41
	6.2. MHC I and MHC II Ag Presentation by DCs Put in	
	Contact with Parasites or <i>Leishmania</i> Ags	43
	6.3. Possible Mechanisms used by <i>Leishmania</i> spp.	
	to Limit Ag Presentation by DCs	48
	6.4. DCs and the Polarization of <i>Leishmania</i> -Specific CD4	
_	T Lymphocytes.	49
7.	The Potential of Infected APCs or APCs Loaded with Leishmania	= 0
	Antigens as Vaccines or Therapeutic Agents	50
	7.1. APCs as Vaccines	50
~	7.2. APCs as Therapeutic Agents.	53
8.		53
		55
	кетегепсез	56

#### ABSTRACT

Identification of macrophages as host cells for the mammalian stage of *Leishmania* spp. traces back to about 40 years ago, but many questions concerning the ways these parasites establish themselves in these cells, which are endowed with potent innate microbicidal mechanisms, are still unanswered. It is known that microbicidal activities of macrophages can be enhanced or induced by effector T lymphocytes following the presentation of antigens via MHC class I or class II molecules expressed at the macrophage plasma membrane. However,

*Leishmania* spp. have evolved mechanisms to evade or to interfere with antigen presentation processes, allowing parasites to partially resist these T cell-mediated immune responses. Recently, the presence of *Leishmania* amastigotes within dendritic cells has been reported suggesting that they could also be host cells for these parasites. Dendritic cells have been described as the only cells able to induce the activation of naive T lymphocytes. However, certain *Leishmania* species infect dendritic cells without inducing their maturation and impair the migration of these cells, which could delay the onset of the adaptive immune responses as both processes are required for naive T cell activation. This review examines how *Leishmania* spp. interact with these two cell types, macrophages and dendritic cells, and describes some of the strategies used by *Leishmania* spp. to survive in these inducible or constitutive antigen-presenting cells.

#### **1. INTRODUCTORY REMARKS**

#### 1.1. The Life Cycles of *Leishmania* spp.

Leishmania spp. are heteroxenous, digenetic protozoan parasites and as such they live successively in two hosts, namely hematophagous insect vectors known as sand flies and some mammals playing the role of reservoirs, from which these infectious agents can be transmitted to other organisms of the same species or of a different species, including humans (for a review see Peters and Killick-Kendrick, 1987a; Schnur and Greenblatt, 1995). In female sand flies, Leishmania spp. exist extracellularly in the lumen of the digestive tract where they adopt a flagellated, elongated promastigote form and go through several differentiation stages. After a differentiation process called metacyclogenesis, promastigotes infective for mammals, termed metacyclic promastigotes, accumulate in the anterior parts of the digestive tract, from where they can be inoculated into the dermis of mammals during a blood meal (Rogers et al., 2002). In mammals, Leishmania spp. are obligate intracellular parasites. Indeed, after the bite of an infected sand fly, at least some of the injected metacyclics are rapidly engulfed by resident dermal phagocytic cells or cells rapidly recruited from the epidermis or the blood. During the early stages of the infection, a large part of the cells internalizing parasites appears to be macrophages ( $M\Phi s$ ), inside which promastigotes differentiate into egg-shaped amastigotes devoid of the external flagellum. This process takes several days and occurs within organelles named parasitophorous vacuoles (PVs), the morphology of which, and at least certain properties vary with different *Leishmania* species (Antoine *et al.*, 1998; Courret *et al.*, 2001). The life cycle is completed when a sand fly takes a blood meal on a parasitized mammal. During this process, the vector can be infected by free amastigotes or by infected mammalian cells located in the skin dermis. In the gut of the insect, the amastigotes differentiate rapidly into promastigotes. As an example, the cycle of *L. amazonensis* is presented in Figure 1.

Humans can also be infected by numerous Leishmania species, but for most of them they are accidental hosts. About 12 million people distributed in 88 countries are suffering from leishmaniasis in the world, and it is estimated that 2 million new cases arise each year. In Europe, Africa and Asia, L. donovani, L. infantum, L. major, L. tropica and L. aethiopica are the main species infecting humans, whereas in South and Central America mainly L. chagasi, L. mexicana, L. amazonensis, L. guyanensis and L. braziliensis are responsible for leishmaniases. According to the Leishmania species initiating infection and their genetic/immunologic status, humans can remain asymptomatic or display more or less severe pathologic processes. Four major forms of human leishmaniases have been described: cutaneous, diffuse cutaneous, mucocutaneous and visceral. Cutaneous leishmaniases are generally benign. Parasites develop locally in the skin at the sites where infected sand flies have inoculated metacyclic promastigotes. In contrast, visceral leishmaniases are fatal in the absence of treatment. In these forms, parasites develop mainly in the liver, the spleen and bone marrow (for a review see Peters and Killick-Kendrick, 1987b; Schnur and Greenblatt, 1995).

As to the wild mammalian reservoirs, which in many *Leishmania* life cycles are rodents, they are generally asymptomatic after infection or develop mild pathologies (Lainson and Shaw, 1979).



maintenance of infection

*Figure 1* Life cycle of *Leishmania amazonensis*. This *Leishmania* species lives alternatively in the sand fly *Lutzomyia flaviscutellata* and in several rodents, especially in *Proechymis* spp. that are considered as the main reservoirs. *L. amazonensis* is endemic in 17 countries of South and Central America and is present mainly in wet forests of the Amazonian Basin. Humans can be incidentally infected by this *Leishmania* species when they penetrate forest areas but they play no role in the maintenance of the natural transmission cycle. See the text for the description of the different steps of the cycle.

#### 1.2. "Classical and Natural Experimental Models" of Leishmaniases

#### 1.2.1. "Classical experimental models"

The parasite infections due to *Leishmania* spp. have been the object of numerous and detailed studies for at least 15 years. Although mice are not natural hosts for Leishmania, inbred laboratory mice inoculated with these parasites have been widely used as experimental hosts for elucidating and characterizing the immunoparasitic processes involved in cutaneous and visceral leishmaniases. However, the "classical models" of leishmaniases are quite different from the situation in nature. They have typically relied on the inoculation of a high number of parasites  $(10^6 - 10^8 \text{ promastigotes, usually in})$ stationary phase and thus heterogeneous, or sometimes lesionderived amastigotes, which are not the life cycle stage introduced into the mammalian host by the sand fly bite) into subcutaneous sites (generally the footpad) or intravenously. These protocols are very far from the natural infections where it has been estimated that vector sand flies inoculate 10 to 1000 metacyclic promastigotes into a dermal site (ear, tail, top of the foot).

Host genetic factors controlling both the innate and adaptive immune responses, and consequently the infection outcomes have been discovered using these "classical models". For example, *L. major* parasites induce progressive cutaneous disease in BALB/c mice that are unable to control parasite expansion at the site of inoculation and in the draining lymph node. As a result, BALB/c mice are considered susceptible to *L. major*. In contrast, other strains (C57BL/ 6 or B10.D2) are considered resistant because the transient lesions that develop at the site of inoculation heal, parasite multiplication is controlled and they develop protective immunity as reflected by resistance to reinfection. However, a low number of amastigotes persist in mice clinically cured and immune to re-infection. Localization of these parasites is still a matter of debate but it seems clear that they are involved in the maintenance of long-lasting immunity. It has clearly been demonstrated that resistance of mice to primary infection with *L. major* is linked to the IL-12 driven activation/expansion of *Leishmania*-reactive CD4 Th1 cells also known as inflammatory CD4 T cells. This lymphocyte subset produces IFN- $\gamma$ , which contributes to the activation of macrophages (M $\Phi$ s) and the nitric oxide (NO) dependent-killing and/or stasis of the intracellular amastigotes. On the other hand, mouse susceptibility to *L. major* has been correlated with the development of a Th2 type response (mediated by CD4 Th2 cells also known as helper CD4 T cells) and the inability to generate a sufficiently potent Th1 type response. In these susceptible mice, the production of cytokines such as IL-4, IL-13, IL-10, TGF- $\beta$  preventing and/or down regulating the IFN- $\gamma$ -dependent macrophage activation is thought to participate in sustained disease development (for a review see Reiner and Locksley, 1995; Sacks and Noben-Trauth, 2002).

It is important to stress that the scenario described above does not take into account the role of parasite genetic factors in determining the disease outcome. There is evidence that it does not apply to all *Leishmania* infections and events may differ according to the infecting *Leishmania* species. For instance, most inbred strains of mice, otherwise resistant to *L. major*, are susceptible to *L. amazonensis*, a situation that, for at least some mouse strains, results from an impaired Th1 type response rather than an enhanced Th2 type response (Afonso and Scott, 1993).

Although this point is still being debated, a role for CD8 T lymphocytes in the resolution of primary murine *L. major* or *L. amazonensis* infections has been reported repeatedly (for a review see Milon *et al.*, 1995). After their activation/differentiation, these cells acquire cytotoxic properties but they are also the source of cytokines and especially of IFN- $\gamma$ .

#### 1.2.2. "Natural experimental models"

Recently, more "natural models" of *Leishmania* infections mimicking as much as possible the natural infections of wild mammals acting as reservoirs were set up in C57BL/6 and BALB/c mice. They rely on the